This research was completed on
Estimates suggest around 700,000 of the world’s babies die or develop disabilities each year because of a condition called neonatal encephalopathy (NE), which can leave the brain permanently damaged.1 Often caused by a shortage of oxygen to the brain, NE puts a baby’s life in immediate danger. Cooling a baby’s temperature down for three days after birth gives them a better chance of surviving and escaping disability. Sadly though, this doesn’t save all babies. Professor Nikki Robertson, of University College London, is investigating whether drug treatment might boost the benefits of cooling and improve babies’ chances.
How are babies’ lives affected now?
“Around 1,300 babies develop a life-threatening brain condition called neonatal encephalopathy, or NE, each year in the UK,” says Professor Robertson.1,2
NE affects newborn babies in the first hours or days of life, often with devastating results. “Sadly, many babies with NE lose their lives,” says Professor Robertson. “Those who survive can develop serious lifelong problems such as cerebral palsy, epilepsy, learning difficulties and deafness.”
Cooling a baby’s temperature down by 3°C for three days – starting as soon as possible after birth – improves their chances of surviving and escaping disability.
“Cooling therapy has revolutionised the treatment of babies with NE and it is now routine in the UK,” says Professor Robertson. “Unfortunately though, cooling doesn’t benefit every baby. Experience in the UK suggests more than 40 per cent of these babies still die or develop a lifelong disability.”3
We urgently need new treatments that work with cooling to improve babies’ chances.
How could this research help?
“Preliminary evidence suggests a drug called magnesium sulphate might boost the benefits of cooling and improve the chances of babies with NE,” says Professor Robertson. “We are investigating the potential benefits of this combination treatment in the laboratory.”
The first aim is to identify what dose of magnesium sulphate is safest. The second aim is to find out whether using this drug in combination with cooling might increase the protective effect of treatment on the brain.
“Magnesium sulphate would be a very attractive treatment for babies with NE as it is inexpensive and widely available,” says Professor Robertson. “If our laboratory work goes well, a clinical trial in babies could be underway quite soon. Our ultimate aim is to save the lives of more babies with NE and give those who survive a better quality of life by sparing them from serious, lifelong disabilities.”
1. Lee ACC et al. Intrapartum-related neonatal encephalopathy incidence and impairment at regional and global levels for 2010 with trends from 1990. Pediatric Research 2013; 74: 50-72.
2. Office for National Statistics. Annual Mid-year Population Estimates, 2011 and 2012. http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-uk--... Website accessed 7 October 2014.
3. Azzopardi D et al. Implementation and conduct of therapeutic hypothermia for perinatal asphyxial encephalopathy in the UK – analysis of national data. PLOS One 2012; 7(6): e38504.
|Project Leader||Professor Nikki Robertson MB ChB, PhD|
|Project Team||Professor Xavier Golay PhDDr Ilias Tachtsidis PhDDr Bobbi Fleiss PhDProfessor Pierre Gressens PhD|
|Project Location||Institute for Women’s Health, University College London|
|Project Location Other||Institute of Neurology, University College LondonMedical Physics and Bioengineering, University College LondonCentre for the Developing Brain, Kings College London|
|Project duration||1.5 years|
|Date awarded||25 July 2014|
|Project start date||23 March 2015|
|Project end date||31 August 2017|
We do not provide medical advice. If you would like more information about a condition or would like to talk to someone about your health, contact NHS Choices or speak to your GP. Please see our useful links page for some links to health information, organisations we are working with and other useful organisations. We hope you will find these useful. We are not responsible for the content of any of these sites.